Healthcare / Drug Manufacturers - Specialty & GenericKSE
$45600.00
-3200.00 (-6.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $51.3B · quality 85.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.05T
P/E
18.0x
↓EV/EBITDA
10.0x
↓ROE
16.7%
↑Gross Margin
46.3%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.2%
FCF CAGR
+10.7%
FCF margin
7.8%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $775.30B · net income $61.51B · FCF $60.28B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $775.30B | $775.30B | $719.38B | $748.53B | $684.35B |
| Net Income | $61.51B | $61.51B | $65.04B | $37.01B | $31.89B |
| EBITDA | $112.01B | $112.01B | $111.55B | $89.97B | $71.59B |
| EPS | 2534.00 | 2534.00 | 2644.00 | 1474.00 | 1242.15 |
| Gross Margin | 46.3% | 46.3% | 45.0% | 44.8% | 42.1% |
| Operating Margin | 12.2% | 12.2% | 11.5% | 13.5% | 9.2% |
| Net Margin | 7.9% | 7.9% | 9.0% | 4.9% | 4.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.28 | 0.64 | 0.87 |
| Current Ratio | 1.46 | 1.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $60.28B | $60.28B | $51.25B | $46.45B | $44.41B |
| Returns | |||||
| ROE | 16.7% | 16.7% | 19.7% | 13.9% | 13.3% |
| Valuation | |||||
| P/E | 18.00 | 18.00 | 22.92 | 42.20 | 48.28 |
| EV/EBITDA | 10.02 | 10.02 | 14.09 | 19.07 | 23.96 |
| P/B | 3.00 | 3.00 | 4.52 | 5.88 | 6.41 |
| Growth & Yield | |||||
| Revenue Growth | 7.8% | 7.8% | -3.9% | 9.4% | — |
| EPS Growth | -4.2% | -4.2% | 79.4% | 18.7% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.9%
EPS terminal req.
$4046.24
Spread vs growth
-21.0%
5Y implied EPS CAGR
14.1%
EPS terminal req.
$4895.95
Spread vs growth
-18.2%
10Y implied EPS CAGR
12.0%
EPS terminal req.
$7884.98
Spread vs growth
-16.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.9%
Start / end P/E
23.1x → 18.0x
EPS bridge
2644.00 → 2534.00
Residual
+0.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.